Shares of Curis, Inc. (NASDAQ:CRIS) have earned an average recommendation of “Hold” from the six research firms that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $6.50.
A number of research firms have weighed in on CRIS. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Guggenheim assumed coverage on Curis in a research note on Monday, October 23rd. They set a “buy” rating and a $7.00 target price for the company.
Curis (NASDAQ CRIS) opened at $0.59 on Friday. The firm has a market capitalization of $97.38, a P/E ratio of -1.52 and a beta of 1.56. Curis has a fifty-two week low of $0.57 and a fifty-two week high of $3.22. The company has a debt-to-equity ratio of 1.24, a current ratio of 5.15 and a quick ratio of 5.15.
In other Curis news, CEO Ali Ph.D. Fattaey bought 50,000 shares of Curis stock in a transaction dated Wednesday, November 15th. The stock was bought at an average cost of $1.06 per share, for a total transaction of $53,000.00. Following the purchase, the chief executive officer now owns 115,890 shares in the company, valued at approximately $122,843.40. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.07% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Curis by 62,201.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock valued at $3,691,000 after buying an additional 2,377,975 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Curis by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 4,955,068 shares of the biotechnology company’s stock valued at $9,365,000 after buying an additional 127,443 shares during the last quarter. State Street Corp boosted its stake in shares of Curis by 10.4% during the 2nd quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after buying an additional 175,424 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in shares of Curis by 10.4% during the 3rd quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after buying an additional 2,500,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Curis by 1.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 1,880 shares during the last quarter. Institutional investors own 55.26% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Curis, Inc. (CRIS) Given Average Recommendation of “Hold” by Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/03/curis-inc-cris-given-average-recommendation-of-hold-by-analysts.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.